Treatment Guidelines: Schizophrenia

American Psychiatric Association (APA)

• Practice guideline for the treatment of patients with schizophrenia (2020)

British Association for Psychopharmacology (BAP)

• Evidence-based guidelines for the pharmacological treatment of schizophrenia (2020)

Canadian Psychiatric Association

• Guidelines for pharmacotherapy of schizophrenia in adults (2017)

European Psychiatric Association (EPA)

• Guidance on treatment of cognitive impairment in schizophrenia (2022)
• Guidance on treatment of negative symptoms in schizophrenia (2021)

Indian Psychiatric Society (IPS)

• Clinical Practice Guidelines for the Management of Schizophrenia in Children and Adolescents (2019)
• Clinical Practice Guidelines for Management of Schizophrenia (2017)

International Guidelines for Algorithmic Treatment (INTEGRATE) 

• INTEGRATE: International Guidelines for the Algorithmic Treatment of Schizophrenia (2025)

Japanese Society of Neuropsychopharmacology (JSNP)

• Guideline for Pharmacological Therapy of Schizophrenia (2021)

National Institute for Health and Care Excellence (NICE)

• Psychosis and schizophrenia in children and young people: recognition and management (2013; updated 2016)
• Psychosis and schizophrenia in adults: prevention and management (2014)

World Federation of Societies of Biological Psychiatry (WFSBP)

• Part 3: Management of special circumstances in the treatment of schizophrenia: depression, suicidality, substance use disorders and pregnancy and lactation (2015)
• Part 2: Long-term treatment of schizophrenia and management of antipsychotic-induced side effects (2013)
• Part 1: Acute treatment of schizophrenia and management of treatment resistance (2012)

VA/DoD Clinical Practice Guidelines

• Management of First-Episode Psychosis and Schizophrenia (2023)

Reviewer 1: Brooke Bernu, PharmD, BCPS, BCPP
Reviewer 2: Abby Stocks, PharmD, BCPP
2026-2027 AAPP Resident and New Practitioner Committee